Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Wall Street Beat
Abbott to expand medical device footprint? | Medtech Wall Street news for the week of May 12, 2014
Spinal firm K2M’s $120M IPO hits the mark | MassDevice.com On Call
MASSDEVICE ON CALL — K2M Group’s (NSDQ:KTWO) initial public offering landed right on target with $120 million in net proceeds, even though the company lowered its per-share price.
Steris closes $165M IMS buy, takes $20.5M charge for restructuring in Q4
Valeant pledges to sweeten $47B bid for Allergan
Device makers take big writedowns on renal denervation
Allergan board spurns Valeant’s $47B offer
Cardinal Health closes $320M AccessClosure buy
Cardinal Health (NYSE:CAH) said today that it closed its $320 million all-cash acquisition of AccessClosure and its Mynx extravascular closure technology.
The Mynx biodegradable sealant products are designed to close off the femoral artery and then dissolve within 30 days.
Abbott may look to expand medical device business footprint
K2M prices IPO under range at $132M
K2M Group cut the price on its initial public offering to $15 per share, with trading in the stock slated to begin today on the NASDAQ exchange under the KTWO symbol.